参考文献/References:
[1]Wesseling P,Capper D.WHO 2016 Classification of gliomas[J].Neuropathol Appl Neurobiol,2018,44(2):139-150. [2]Liang S,Fan X,Zhao M,et al.Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy[J].Cancer Med,2019,8(10):4527-4535. [3]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2):115-132. [4]Stylli SS.Novel Treatment Strategies for Glioblastoma[J].Cancers(Basel),2020,12(10):2883. [5]Bai J,Varghese J,Jain R.Adult Glioma WHO Classification Update,Genomics,and Imaging:What the Radiologists Need to Know[J].Top Magn Reson Imaging,2020,29(2):71-82. [6]Brito C,Azevedo A,Esteves S,et al.Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with:EGFR amplification,TERT mutations,PTEN deletion and MGMT methylation[J].BMC Cancer,2019,19(1):968. [7]Xu S,Tang L,Li X,et al.Immunotherapy for glioma:Current management and future application[J].Cancer Lett,2020(476):1-12. [8]Zhang H,Xu Q,Stanislaw K,et al.BAR:an apoptosis regulator at the intersection of caspases and Bcl-2 family proteins[J].Proc Natl Acad Sci U S A,2000(97):2597-2602. [9]Roth W,Kermer P,Krajewska M,et al.Bifunctional apoptosis inhibitor(BAR)protects neurons from diverse cell death pathways[J].Cell Death Differ,2003,10(10):1178-1187. [10]Kristensen BW,Priesterbach-Ackley LP,Petersen JK,et al.Molecular pathology of tumors of the central nervous system[J].Ann Oncol,2019,30(8):1265-1278. [11]Tamtaji OR,Mirzaei H,Shamshirian A,et al.New trends in glioma cancer therapy:Targeting Na+ /H+ exchangers[J].J Cell Physiol,2020,235(2):658-665. [12]Wu F,Li GZ,Liu HJ,et al.Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma[J].J Pathol,2020,251(3):272-283. [13]Miller JJ,Shih HA,Andronesi OC,et al.Isocitrate dehydrogenase-mutant glioma:Evolving clinical and therapeutic implications[J].Cancer,2017,123(23):4535-4546. [14]Zhu Z,Lan Y,Wang L,et al.A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients[J].BMC Cancer,2020,20(1):1072. [15]Miller JJ,Loebel F,Juratli TA,et al.Accelerated progression of IDH mutant glioma after first recurrence[J].Neuro Oncol,2019,21(5):669-677.
相似文献/References:
[1]吴 刚,袁华兵.阿瑞匹坦对于改善Ⅲ~Ⅳ期颅内胶质瘤患者CINV的研究[J].医学信息,2019,32(13):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
WU Gang,YUAN Hua-bing.Study on the Effect of Aprepitant on Improving CINV in Patients with
Stage III~IV Intracranial Glioma[J].Medical Information,2019,32(07):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
[2]张 诚,丁建玲,麦麦提依明·托合提,等.P53、EGFR在胶质瘤组织中的表达及意义[J].医学信息,2020,33(07):94.[doi:10.3969/j.issn.1006-1959.2020.07.026]
ZHANG Cheng,DING Jian-ling,McMatti Yiming Tohetti,et al.Expression and Significance of P53 and EGFR in Glioma Tissues[J].Medical Information,2020,33(07):94.[doi:10.3969/j.issn.1006-1959.2020.07.026]
[3]尹 江,张志杰,贺智敏.miRNA205在神经胶质瘤细胞放疗敏感性中的作用[J].医学信息,2021,34(13):1.[doi:10.3969/j.issn.1006-1959.2021.13.001]
YIN Jiang,ZHANG Zhi-jie,HE Zhi-min.The Role of miRNA205 in the Sensitivity of Glioma Cells to Radiotherapy[J].Medical Information,2021,34(07):1.[doi:10.3969/j.issn.1006-1959.2021.13.001]
[4]刘钰婵,张 威,邱 俊,等.感兴趣区选取数量对脑胶质瘤IVIM参数测量的影响[J].医学信息,2022,35(01):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
LIU Yu-chan,ZHANG Wei,QIU Jun,et al.The Influence of the Number of Selected ROIs on the Measurement of IVIM Parameters of Glioma[J].Medical Information,2022,35(07):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
[5]张 群,田秋思,唐铖铖,等.基于生物信息学检测NSUN2基因在胶质瘤中的表达及临床意义[J].医学信息,2022,35(04):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
ZHANG Qun,TIAN Qiu-si,TANG Cheng-cheng,et al.Detection of NSUN2 Gene Expression in Glioma Based on Bioinformatics and its Clinical Significance[J].Medical Information,2022,35(07):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
[6]谢 炯,戚 继.PEX基因转染人脐带间充质干细胞的体外培养及鉴定[J].医学信息,2023,36(10):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
XIE Jiong,QI Ji.In Vitro Culture and Identificationg of Human Umbilical Cord Mesenchymal Stem Cells Modified by PEX Gene[J].Medical Information,2023,36(07):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
[7]胡彩虹,王志浩,方思琪,等.CARM1在胶质瘤发生发展中的作用研究[J].医学信息,2022,35(06):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]
HU Cai-hong,WANG Zhi-hao,FANG Si-qi,et al.The Role of CARM1 in the Development of Glioma[J].Medical Information,2022,35(07):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]